<DOC>
	<DOCNO>NCT00129194</DOCNO>
	<brief_summary>The primary purpose study assess safety pharmacokinetics KP-1461 give every 12 hour 14 day administer HIV+ patient fail multiple highly active antiretroviral therapy ( HAART ) regimens . Patients currently HAART require discontinue HAART medication 6 week screen eligibility determine .</brief_summary>
	<brief_title>Study KP-1461 Treatment HIV Positive Patients Who Have Failed Multiple HAART Regimens</brief_title>
	<detailed_description>KP-1461 carbamate prodrug active nucleoside , KP-1212 . KP-1212 incorporated proviral DNA . After multiple round replication , KP-1212 increase high inherent mutation rate HIV beyond threshold viability , process call `` viral decay acceleration '' . KP-1212 unique conventional nucleoside reverse transcriptase inhibitor insert mutation randomly across entire 10,000 nucleotide HIV genome exert selective pressure target specific viral cellular process , thus potentially avoid drug resistance .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>CD4 &gt; 100 cells/mm3 Viral load 2,500 200,000 copies/mL Exposure least 2 different HAART regimens contain NRTI ( ) , NNRTI ( ) , 2 PI ( ) , exclude Ritonavir , minimum 4 month document resistance least 3 4 class approve antiretroviral drug . Few , , effective treatment option available HBsAb ( hepatitis B ) positive serology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>